Endo International plc has kicked off a series of more than 200 patient events that will be held across the United States as part of Butt First, a new direct-to-consumer awareness campaign designed to educate women about Endo Aesthetics’ Qwo (collagenase clostridium histolyticum-aaes). QWO nabbed U.S. FDA approval in July 2020 and is an injectable treatment for moderate to severe cellulite in the buttocks of adult women. QWO is available in aesthetic practices across the country.
“Butt First conveys factual information about the causes and treatment of cellulite, while also striking an emotional connection with women,” says Rob Catlin, senior vice president and general manager, Endo Aesthetics. “The multi-channel campaign encourages women who are bothered by their cellulite to start a conversation with their aesthetic provider to find out if treatment with QWO is an appropriate option.”
“Cellulite has never been an easy topic for patients to raise with their aesthetic physicians and vice versa,” adds Kim Nichols MD, a Connecticut-based, board-certified dermatologist and host of one of the upcoming patient events. “With the Butt First campaign, Endo Aesthetics is offering patients and physicians a judgment-free way to discuss an issue that affects most adult women of all races, ages, body types, and fitness levels—cellulite. I look forward to seeing current and future patients empowered by these open and honest conversations.”
Over the next few months, hundreds of QWO patient events will take place at aesthetic practices across the United States. They’re designed to provide a fun and educational environment where women can learn about cellulite and whether QWO is the right treatment for them. These events allow all attendees to feel empowered to put themselves and their “butt first.”
Women interested in attending an event in their area can find a QWO provider on www.qwo.com and ask them about their upcoming Butt First event.